Boulder gene-editing company raises $55.5M, will hire scientists

A Boulder biotech that's exploring gene-editing technology said it's raised $55.5 million in a Series C round of funding. Inscripta, which used to be known as Muse Biotechnology, said the latest funding round was led by Mérieux Développement and Paladin Capital Group. Additional participants included all previous Inscripta investors: Venrock, Foresite, MLS Capital, and NanoDimension. The fundraising comes just a y ear after Muse bio raised $23 million in a Series B round of funding. The latest…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news